Vical Incorporated  

(Public, NASDAQ:VICL)   Watch this stock  
2.48
+0.03 (1.22%)
Jun 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.45 - 2.52
52 week 2.05 - 4.59
Open 2.46
Vol / Avg. 86,873.00/57,375.00
Mkt cap 27.19M
P/E     -
Div/yield     -
EPS -0.88
Shares 11.10M
Beta 2.24
Inst. own 24%
Jun 21, 2017
Vical Inc at Biotechnology Industry Organization (BIO) International Convention
May 15, 2017
Q1 2017 Vical Inc Earnings Call - Webcast
May 11, 2017
Q1 2017 Vical Inc Earnings Release (Estimated)
May 2, 2017
Vical Incorporated - Special Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -88.11% -61.75%
Operating margin -90.89% -63.15%
EBITD margin - -56.27%
Return on average assets -21.84% -17.56%
Return on average equity -25.82% -19.82%
Employees 73 -
CDP Score - -

Address

10390 Pacific Center Ct
SAN DIEGO, CA 92121-4340
United States - Map
+1-858-6461100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Officers and directors

R. Gordon Douglas M.D. Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Vijay B. Samant President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony Alan Ramos Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Age: 50
Bio & Compensation  - Reuters
Mammen P. Mammen Jr. Vice President - Clinical Vaccines
Age: 51
Bio & Compensation  - Reuters
Lawrence Russell Smith Vice President - Vaccine Research
Age: 54
Bio & Compensation  - Reuters
Thomas E. Shenk Ph.D. Director
Bio & Compensation  - Reuters
Richard M. Beleson Independent Director
Age: 61
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 56
Bio & Compensation  - Reuters
Robert C. Merton Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
George J. Morrow Independent Director
Age: 64
Bio & Compensation  - Reuters